| Date Filed | Type | Description |
| 10/10/2023 |
8-K
| Other Events Interactive Data |
| 10/02/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 10/02/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/11/2023 |
8-K
| Investor presentation |
| 08/09/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/09/2023 |
4
| BRAENDER LORI J (SVP, General Counsel) has filed a Form 4 on Aquestive Therapeutics, Inc.|
Txns:
| Granted 75,000 rights
@ $0 |
|
| 08/09/2023 |
4
| Barber Daniel (President and CEO) has filed a Form 4 on Aquestive Therapeutics, Inc.|
Txns:
| Granted 223,500 rights
@ $0 |
|
| 08/09/2023 |
4
| Marshall Ken W. (SVP, Chief Commercial Officer) has filed a Form 4 on Aquestive Therapeutics, Inc.|
Txns:
| Granted 75,000 rights
@ $0 |
|
| 08/09/2023 |
4
| Boyd Peter E. (See Remark) has filed a Form 4 on Aquestive Therapeutics, Inc.|
Txns:
| Granted 50,000 rights
@ $0 |
|
| 08/09/2023 |
4
| Kraus Carl N (Chief Medical Officer) has filed a Form 4 on Aquestive Therapeutics, Inc.|
Txns:
| Granted 150,000 shares
@ $0 |
|
| 08/09/2023 |
4
| Wargacki Stephen (SVP, Research & Development) has filed a Form 4 on Aquestive Therapeutics, Inc.|
Txns:
| Granted 67,500 rights
@ $0 |
|
| 08/09/2023 |
4
| TOTH A ERNEST JR (SVP, CFO) has filed a Form 4 on Aquestive Therapeutics, Inc.|
Txns:
| Granted 70,000 rights
@ $0 |
|
| 08/09/2023 |
4
| Schobel Alexander Mark (Chief Innovation/Tech Officer) has filed a Form 4 on Aquestive Therapeutics, Inc.|
Txns:
| Granted 50,000 rights
@ $0 |
|
| 08/09/2023 |
4
| Jung Cassie (SVP, Operations) has filed a Form 4 on Aquestive Therapeutics, Inc.|
Txns:
| Granted 55,000 rights
@ $0 |
|
| 08/07/2023 |
8-K
| Investor presentation, Quarterly results |
| 08/07/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/02/2023 |
8-K
| Quarterly results |
| 07/27/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 06/30/2023 |
3
| Kraus Carl N (CHIEF MEDICAL OFFICER) has filed a Form 3 on Aquestive Therapeutics, Inc. |
| 06/29/2023 |
8-K
| Investor presentation |
| 05/31/2023 |
8-K
| Investor presentation |
| 05/05/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/05/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/05/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/05/2023 |
4
| BRAENDER LORI J (SVP, General Counsel) has filed a Form 4 on Aquestive Therapeutics, Inc.|
Txns:
| Granted 75,000 rights
@ $0 |
|
| 05/05/2023 |
4
| Barber Daniel (President and CEO) has filed a Form 4 on Aquestive Therapeutics, Inc.|
Txns:
| Granted 223,500 rights
@ $0 |
|
| 05/05/2023 |
4
| Marshall Ken W. (SVP, Chief Commercial Officer) has filed a Form 4 on Aquestive Therapeutics, Inc.|
Txns:
| Granted 75,000 rights
@ $0 |
|
| 05/05/2023 |
4
| Jung Cassie (SVP, Operations) has filed a Form 4 on Aquestive Therapeutics, Inc.|
Txns:
| Granted 55,000 rights
@ $0 |
|
| 05/05/2023 |
4
| Boyd Peter E. (See Remark) has filed a Form 4 on Aquestive Therapeutics, Inc.|
Txns:
| Granted 50,000 rights
@ $0 |
|
| 05/02/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/02/2023 |
8-K
| Quarterly results |
| 05/02/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
|